Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Research and Innovation Action · Running

OPADE Optimise and predict antidepressant efficacy for patient with major depressive disorders using multi-omics analysis and AI-predictive tool

Coordinator
Fondazione Ebris, Italy
Runs
1 December 2022 to 31 May 2027
Status
Running
EU funding
€10.0m
Total cost
€10.0m
Partners
14 organisations in 10 countries
Type
Research and Innovation Action
Grant agreement
101095436

What the project is doing

In the project's own words, from its summary on CORDIS.

280M of people worldwide suffers from major depressive disorders (MDD). Although a well-populated therapeutic landscape of anti-depre280M of people worldwide suffers from major depressive disorders (MDD). Although a well- populated therapeutic landscape of anti-depressants, the number of patients in remission is particularly low with not more than 6% of the patients who benefit from the current therapeutic journey. OPADE objective is to identify key biomarkers that support the decision-making process of the healthcare providers.

The project focuses on the microbiota – brain -axis which plays a major role in mental health and in particular MDD. Through clinical investigations, the consortium partners will study the combination between genetics, epigenetics, microbiome and inflammatory networks to:-Establish patient profiles to predict and optimise the efficacy of the antidepressants prescribed with an increase in the remission rate and reduction of impairment of real-life functioning,-Establish the possible correlation between neuroinflammatory indices, target indicators of the microbiome, metabolomics, immune-profile linked, epigenomic, enzymatic algorithms,-Evaluate molecular and non-molecular biomarkers that may represent predictive indices of recurrence-Discover new molecular targets for a personalised approach,-Improve the diagnostic accuracy for primary prevention,-Evaluate retrospectively, using accurate anamnesis, the onset of depressive symptoms in adolescence.-Establish how much and to what extent do blood biomarkers correlate with other specific biomarkers350 patients between 14 and 50 years will be recruited in 4 EU and international countries for 24 months.

Real-time EEG and patient cognitive assessment will be collected with blood, stool and saliva samples. Results and analysis will be used to train the AI / ML predictive tool, the main outcome of the project. A patient empowerment tool will be deployed over the project duration.

Topics

Who is involved

OrganisationCityCountryRole
Fondazione EbrisSalernoItalyCoordinator
Perseus BiomicsTienenBelgiumParticipant
Fundacion Universitaria SanitasBogotaCOParticipant
Mama Health Technologies GmbHPotsdamGermanyParticipant
Protobios OuTallinnEstoniaParticipant
Biokeralty Research Institute AieVitoria-GasteizSpainParticipant
Fundacio EurecatCerdanyola Del Valles (Barcelona)SpainParticipant
Fundacio Institut D'investigacio Biomedica De Girona Doctor Josep TruetaGironaSpainParticipant
CephalgoStrasbourgFranceParticipant
Ceinge Biotecnologie Avanzate Franco Salvatore ScarlNapoliItalyParticipant
Universita Degli Studi Di SienaSienaItalyParticipant
Stichting Universitaire En Algemene Kinder - En Jeugdpsychiatrie Noord-NederlandAssenNetherlandsParticipant
Artificial Intelligence Expert SRLCluj NapocaRomaniaParticipant
Istanbul Medipol UniversitesiIstanbulTürkiyeParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI